The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jinsoo | - |
dc.contributor.author | Jung, Yoon Yang | - |
dc.contributor.author | Lee, Jung Hoon | - |
dc.contributor.author | Hong, Mineui | - |
dc.contributor.author | Hwang, Hye-Won | - |
dc.contributor.author | Hong, Soon Auck | - |
dc.contributor.author | Hong, Sook-Hee | - |
dc.date.accessioned | 2023-03-08T10:49:18Z | - |
dc.date.available | 2023-03-08T10:49:18Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.issn | 1423-0232 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/62345 | - |
dc.description.abstract | Background: Sex-determining region Y-box 2 (SOX2) is a transcriptional factor that drives embryonic stem cells to neuroendocrine cells in lung development and is highly expressed in small-cell lung cancer (SCLC). However, the prognostic role of SOX2 and its relationship with tumor-infiltrating lymphocytes (TILs) has not been determined in SCLC. Herein, we assessed the expression of SOX2 and CD8+ TILs to obtain insights into the prognostic role of SOX2 and CD8+ TILs in limited-stage (LS)-SCLC. Methods: A total of 75 patients with LS-SCLC was enrolled. The SOX2 expression and CD8+ TILs were evaluated by immunohistochemistry. Results: High SOX2 and CD8+ TIL levels were identified in 52 (69.3%) and 40 (53.3%) patients, respectively. High SOX2 expression was correlated with increased density of CD8+ TILs (p = 0.041). Unlike SOX2, high CD8+ TIL numbers were associated with significantly longer progression-free survival (PFS; 13.9 vs. 8.0 months, p = 0.014). Patients with both high SOX2 expression and CD8+ TIL numbers (n = 29, 38.7%) had significantly longer PFS and overall survival (OS) compared to those from the other groups (median PFS 19.3 vs. 8.4 months; p = 0.002 and median OS 35.7 vs. 17.4 months; p = 0.004, respectively). Multivariate Cox regression analysis showed that the combination of high SOX2 expression and CD8+ TIL levels was an independent good prognostic factor for OS (HR = 0.471, 95% CI, 0.250-0.887, p = 0.02) and PFS (HR = 0.447, 95% CI, 0.250-0.801, p = 0.007) in SCLC. Conclusions: Evaluation of the combination of SOX2 and CD8+ TIL levels may be of a prognostic value in LS-SCLC. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KARGER | - |
dc.title | The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1159/000516444 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, v.99, no.8, pp 528 - 538 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000659539900001 | - |
dc.identifier.scopusid | 2-s2.0-85112355941 | - |
dc.citation.endPage | 538 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 528 | - |
dc.citation.title | ONCOLOGY | - |
dc.citation.volume | 99 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Sex-determining region Y-box 2 | - |
dc.subject.keywordAuthor | CD8+tumor-infiltrating lymphocyte | - |
dc.subject.keywordAuthor | Small-cell lung cancer | - |
dc.subject.keywordPlus | TNM-CLASSIFICATION | - |
dc.subject.keywordPlus | PROJECT PROPOSALS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | EDITION | - |
dc.subject.keywordPlus | SOX2 | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.